drugset / Trial / NCT00568334

Study of Two Formulations of GSK Biologicals' Varicella Vaccine

NCT00568334

Phase 2 Completed 244 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety. This present study is undertaken to rule out any negative impact on the immunogenicity and safety of GSK Biologicals' live attenuated varicella virus vaccine.

Timeline

Start
2007-11-01
Primary completion
2008-03-18
Completion
2008-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Varilrix Vaccine Subcutaneous

Indications